Redeye: Acconeer - Robust financing mitigates the downside risks
Redeye states that Acconeer’s Q4 2024 report was mixed, with a slight net sales miss, while EBITDA was above Redeye Research estimates (RRe), adjusting for the postponed order. Acconeer announced an impressively structured SEK50m capital raise that, once finalized, will secure a robust liquidity position. The issuance was rightly met with jubilation. Redeye adjusted its forecast and fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/